Skip to content

ICU医疗

US · ICUI #2287 按市值排名 上市于 1970
162.99 -4.24 -2.54%
实时 - 追踪5344个代码 - 心跳于539秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 1.86 处于历史正常水平 第57百分位
5年平均 1.87 · 在Medical Instruments & Supplies中排名第17/51
市盈率 134.23 高于历史水平 第88百分位
5年平均 158.31 · 前瞻 39.67 · 在Medical Instruments & Supplies中排名第23/27
市销率 1.85 处于历史正常水平 第63百分位
5年平均 1.90 · 前瞻 1.79 · 在Medical Instruments & Supplies中排名第17/51

同业对比 Medical Instruments & Supplies

公司 市值 市盈率(TTM) 市净率 股息率
ICU医疗 (ICUI) 4.08B 136.97 1.89 0.00%
Intuitive Surgical (ISRG) 150.74B 48.93 8.30 0.00%
Becton Dickinson & Co (BDX) 52.23B 57.93 2.14 2.19%
ResMed (RMD) 33.61B 22.91 5.10 1.00%
Alcon (ALC) 31.99B 50.52 1.48 0.53%
Medline (MDLN) 31.55B 68.24 2.73 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★★ 合理价值181.29 经济护城河None 不确定性Medium

当前股价低于晨星合理价值估算11.2%。

合理价值

ICU Medical Inc receives a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 11% discount to our quantitative fair value estimate of $181.29 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The company's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to market value ratio of 1.2 lies in the top 40% compared with global peers. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. We believe this is a sign that shares could be cheap.

The firm's balance sheet is an additional encouraging factor. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. The firm's EBITDA/interest coverage ratio of 3.3, a core component of leverage, falls in the bottom 30% compared with global peers. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. This characteristic further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

经济护城河

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

ICU医疗 讨论区 0 条评论

发表评论